Page last updated: 2024-09-04

vatalanib and pazopanib

vatalanib has been researched along with pazopanib in 10 studies

Compound Research Comparison

Studies
(vatalanib)
Trials
(vatalanib)
Recent Studies (post-2010)
(vatalanib)
Studies
(pazopanib)
Trials
(pazopanib)
Recent Studies (post-2010) (pazopanib)
27642981,1472371,028

Protein Interaction Comparison

ProteinTaxonomyvatalanib (IC50)pazopanib (IC50)
Multidrug resistance-associated protein 4Homo sapiens (human)8.1
Tyrosine-protein kinase ABL1Homo sapiens (human)2.2043
Macrophage colony-stimulating factor 1 receptorHomo sapiens (human)0.21
Cytochrome P450 3A4Homo sapiens (human)0.03
Platelet-derived growth factor receptor betaHomo sapiens (human)0.0837
Cytochrome P450 2D6Homo sapiens (human)0.03
Mast/stem cell growth factor receptor KitHomo sapiens (human)0.0887
Fibroblast growth factor receptor 1Homo sapiens (human)0.1477
Platelet-derived growth factor receptor alphaHomo sapiens (human)0.071
Vascular endothelial growth factor receptor 1 Homo sapiens (human)0.032
Fibroblast growth factor receptor 2Homo sapiens (human)0.14
AcetylcholinesteraseHomo sapiens (human)0.93
Vascular endothelial growth factor receptor 3Homo sapiens (human)0.0467
Vascular endothelial growth factor receptor 2Homo sapiens (human)0.4929
Receptor-interacting serine/threonine-protein kinase 1Homo sapiens (human)0.873
Discoidin domain-containing receptor 2Homo sapiens (human)0.0505
Receptor protein-tyrosine kinase Homo sapiens (human)2.2043

Research

Studies (10)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (10.00)29.6817
2010's9 (90.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Atteridge, CE; Campbell, BT; Chan, KW; Ciceri, P; Davis, MI; Edeen, PT; Faraoni, R; Floyd, M; Gallant, P; Herrgard, S; Hunt, JP; Karaman, MW; Lockhart, DJ; Milanov, ZV; Morrison, MJ; Pallares, G; Patel, HK; Pritchard, S; Treiber, DK; Wodicka, LM; Zarrinkar, PP1
Jeong, KW; Kim, MS; Kim, Y; Lee, GS; Lee, K; Lee, Y; Song, JY1
Hajduk, PJ; Johnson, EF; Kifle, L; Merta, PJ; Metz, JT; Soni, NB1
Russu, WA; Shallal, HM1
Ciceri, P; Davis, MI; Herrgard, S; Hocker, M; Hunt, JP; Pallares, G; Treiber, DK; Wodicka, LM; Zarrinkar, PP1
Cahya, S; Cummins, DJ; Gao, C; Iversen, PW; Nicolaou, CA; Vieth, M; Wang, J; Watson, IA1
Aiche, S; Bassermann, F; Becker, W; Canevari, G; Casale, E; Depaolini, SR; Ehrlich, HC; Felder, ER; Feuchtinger, A; Garz, AK; Gohlke, BO; Götze, K; Greif, PA; Hahne, H; Heinzlmeir, S; Helm, D; Huenges, J; Jeremias, I; Kayser, G; Klaeger, S; Koch, H; Koenig, PA; Kramer, K; Kuster, B; Médard, G; Meng, C; Petzoldt, S; Polzer, H; Preissner, R; Qiao, H; Reinecke, M; Reiter, K; Rueckert, L; Ruland, J; Ruprecht, B; Schlegl, J; Schmidt, T; Schneider, S; Schoof, M; Spiekermann, K; Tõnisson, N; Vick, B; Vooder, T; Walch, A; Wilhelm, M; Wu, Z; Zecha, J; Zolg, DP1
Erdfelder, F; Filipovich, A; Gandhirajan, RK; Gehrke, I; Hallek, M; Hertweck, M; Kreuzer, KA; Paesler, J; Poll-Wolbeck, SJ; Uhrmacher, S1
Döme, B; Török, S1
Cserepes T, M; Döme, B; Rényi-Vámos, F; Török, S1

Reviews

2 review(s) available for vatalanib and pazopanib

ArticleYear
[Possibilities for inhibiting tumor-induced angiogenesis: results with multi-target tyrosine kinase inhibitors].
    Magyar onkologia, 2012, Volume: 56, Issue:1

    Topics: Angiogenesis Inhibitors; Animals; Axitinib; Benzenesulfonates; Humans; Imidazoles; Indazoles; Indoles; Neoplasms; Neovascularization, Pathologic; Niacinamide; Oligonucleotides; Phenylurea Compounds; Phthalazines; Piperidines; Protein Kinase Inhibitors; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Pyrroles; Quinazolines; Receptor Protein-Tyrosine Kinases; Receptors, Fibroblast Growth Factor; Receptors, Platelet-Derived Growth Factor; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Sorafenib; Sulfonamides; Sunitinib

2012
[Nintedanib (BIBF 1120) in the treatment of solid cancers: an overview of biological and clinical aspects].
    Magyar onkologia, 2012, Volume: 56, Issue:3

    Topics: Animals; Antineoplastic Agents; Axitinib; Benzenesulfonates; Carcinoma, Hepatocellular; Clinical Trials as Topic; Colorectal Neoplasms; Digestive System; Enzyme Inhibitors; Female; Genital Neoplasms, Female; Humans; Imidazoles; Indazoles; Indoles; Liver Neoplasms; Lung Neoplasms; Male; Neoplasms; Niacinamide; Oligonucleotides; Phenylurea Compounds; Phthalazines; Piperidines; Prostatic Neoplasms; Protein-Tyrosine Kinases; Pyridines; Pyrimidines; Quinazolines; Receptors, Fibroblast Growth Factor; Receptors, Platelet-Derived Growth Factor; Receptors, Vascular Endothelial Growth Factor; Signal Transduction; Sorafenib; Sulfonamides; Xenograft Model Antitumor Assays

2012

Other Studies

8 other study(ies) available for vatalanib and pazopanib

ArticleYear
A quantitative analysis of kinase inhibitor selectivity.
    Nature biotechnology, 2008, Volume: 26, Issue:1

    Topics: Binding Sites; Enzyme Activation; Humans; Phosphotransferases; Protein Binding; Protein Interaction Mapping; Protein Kinase Inhibitors; Proteome; Quantitative Structure-Activity Relationship

2008
Pharmacophore modeling and virtual screening studies for new VEGFR-2 kinase inhibitors.
    European journal of medicinal chemistry, 2010, Volume: 45, Issue:11

    Topics: Drug Evaluation, Preclinical; Models, Molecular; Protein Kinase Inhibitors; Vascular Endothelial Growth Factor Receptor-2

2010
Navigating the kinome.
    Nature chemical biology, 2011, Volume: 7, Issue:4

    Topics: Drug Design; Pharmacogenetics; Protein Kinases; Proteome; Systems Biology

2011
Discovery, synthesis, and investigation of the antitumor activity of novel piperazinylpyrimidine derivatives.
    European journal of medicinal chemistry, 2011, Volume: 46, Issue:6

    Topics: Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Dose-Response Relationship, Drug; Drug Discovery; Drug Screening Assays, Antitumor; Humans; Models, Molecular; Molecular Structure; Piperazines; Protein Kinase Inhibitors; Protein Kinases; Pyrimidines; Stereoisomerism; Structure-Activity Relationship

2011
Comprehensive analysis of kinase inhibitor selectivity.
    Nature biotechnology, 2011, Oct-30, Volume: 29, Issue:11

    Topics: Catalysis; Drug Design; Enzyme Stability; High-Throughput Screening Assays; Humans; Protein Binding; Protein Kinase Inhibitors; Protein Kinases; Proteomics; Signal Transduction; Substrate Specificity

2011
Selectivity data: assessment, predictions, concordance, and implications.
    Journal of medicinal chemistry, 2013, Sep-12, Volume: 56, Issue:17

    Topics: Computer Simulation; Drug Discovery

2013
The target landscape of clinical kinase drugs.
    Science (New York, N.Y.), 2017, 12-01, Volume: 358, Issue:6367

    Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cytokines; Drug Discovery; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Lung Neoplasms; Mice; Molecular Targeted Therapy; Protein Kinase Inhibitors; Protein Serine-Threonine Kinases; Proteomics; Xenograft Model Antitumor Assays

2017
The vascular endothelial growth factor receptor tyrosine kinase inhibitors vatalanib and pazopanib potently induce apoptosis in chronic lymphocytic leukemia cells in vitro and in vivo.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2010, Jul-01, Volume: 16, Issue:13

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Caspases; Cell Line, Tumor; Dose-Response Relationship, Drug; Humans; Indazoles; Leukemia, Lymphocytic, Chronic, B-Cell; Mice; Phosphorylation; Phthalazines; Protein Kinase Inhibitors; Pyridines; Pyrimidines; Receptors, Vascular Endothelial Growth Factor; Sulfonamides; Xenograft Model Antitumor Assays

2010